Revive Therapeutics files US provisional patent application for oral thin-film psilocybin product following research study

Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF) (FRA:31R) announced the filing of a provisional patent application with the US Patent and Trademark Office (USPTO) for an oral thin-film (OTF) delivery system featuring psilocybin after a successful research study.  The OTF, developed through a research partnership agreement with Reed Research Group at the University of Wisconsin-Madison, offers a unique delivery of psilocybin as a potential treatment option for mental illness, neurological and substance abuse disorders.  The study determined that psilocybin could be incorporated into chitosan-tannin composite hydrogel solutions, which are cast into molds to form stable flexible thin films that then release the psilocybin when dissolved in water. The OTF psilocybin product dissolved in water in less than five minutes with dosage forms ranging between 1 milligrams (mg) and 20 mg. READ: Revive Therapeutics on track to meet planned patient enrollment for its Phase 3 Bucillamine coronavirus trial in second quarter Revive is in discussion with a leading OTF contract manufacturer to assist in the clinical scale-up and manufacturing of the psilocybin product, the company said. Future studies will include evaluation in humans in US Food and Drug Administration (FDA) Phase I and II clinical studies as a potential treatment for various mental illness, neurological and substance abuse disorders. As a result of the study, the Wisconsin Alumni Research Foundation (WARF) submitted a provisional patent application to the UPTSO, titled “Composite Chitosan-Tannin-Active Agent Compositions and Methods of Making and Using Same.” There are a number of advantages and benefits of an orally dissolvable psilocybin thin film, the company said, such as the rapid dissolving and onset of action to the bloodstream, the ease and convenience for patients, the potential of improved therapeutic outcomes and efficacy for underserved diseases and disorders. “We are pleased with the final conclusion of the research work and its successful results, as it validates our drug delivery technology in delivering psychedelic pharmaceuticals and positions our oral thin film psilocybin product to become a potential novel treatment solution for various mental illness, neurological and substance abuse disorders,” Revive CEO Michael Frank said in a statement.  “We continue to focus on building our intellectual property portfolio, advancing our psychedelics-based product pipeline to clinical trials and partnering with leading institutions, such as University of Wisconsin-Madison, which recently pioneered the only master’s program of its kind in the US in therapeutic use of psychoactive drugs.” Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com   Follow him on Twitter @andrew_kessel